News
-
-
-
PRESS RELEASE
ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence
ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, expanding U.S. presence. The strategic acquisition includes FDA-approved specialty medications Prialt® and Quzyttir®